On January 16, 2019, PTC Therapeutics joined Parent Project Muscular Dystrophy for a webinar update to provide the community with an overview of the Translarna development program with a focus on clinical trials that are recruiting.

If you missed the live event, the recording can be found below.

 

 

Watch the Recording

About the presenter

• Francesco Bibbiani, MD
  VP of Clinical Development, PTC Therapeutics
  Francesco Bibbiani is a board-certified neurologist with over 20 year experience in clinical development between the pharmaceutical industry and the Experimental Therapeutic Branch (ETB) of the National Institute of Health (NIH), where we conducted proof of concept trials in several neurological indications. In his past positions, Francesco conducted various clinical trials in Huntington’s disease, Alzheimer disease, and epilepsy, all studies that led to multiple regulatory submissions and approvals with the FDA, EMA and other global regulatory agencies. Currently, he is the Vice President of Clinical Development at PTC Therapeutics, where he leads the Neurological Therapeutic Area.